A wobbly Biogen makes a surprise switch in the executive suite, triggering a renewed burst of M&A chatter
Right on the eve of releasing their Q2 numbers, Biogen $BIIB managed to surprise just about everyone with the news Tuesday night that CFO Jeff Capello — in the hot seat for less than 3 years — had hit the exit, with his replacement set to arrive in a couple of weeks. And speculation immediately turned to figuring out what was afoot, given the high wire act that the big biotech is currently engaged in with aducanumab.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.